Summary of AMP's Early January Trades


In the first week of January AMP started positions in Edge Therapeutics and Zealand Pharma and continued to build its positions in SC Pharmaceuticals and Protagonist Therapeutics.

AMP also further trimmed its Nektar Therapeutics positions which was up 400%+ at the time of the sales; netting AMP ~$27,000 in hypothetical gains.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon